Evolus, Inc. (NASDAQ:EOLS - Get Free Report) CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $60,147.36. Following the completion of the transaction, the chief marketing officer now directly owns 95,671 shares of the company's stock, valued at $1,268,597.46. This represents a 4.53 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Evolus Trading Down 1.6 %
Evolus stock opened at $13.25 on Friday. Evolus, Inc. has a one year low of $9.25 and a one year high of $17.82. The company's fifty day moving average price is $13.36 and its two-hundred day moving average price is $13.91. The company has a market capitalization of $842.53 million, a price-to-earnings ratio of -14.56 and a beta of 1.28. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. KBC Group NV bought a new stake in Evolus during the fourth quarter worth approximately $49,000. IFP Advisors Inc boosted its holdings in shares of Evolus by 17,440.7% during the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after buying an additional 4,709 shares during the period. KLP Kapitalforvaltning AS acquired a new position in Evolus in the 4th quarter valued at $106,000. Rafferty Asset Management LLC bought a new position in Evolus in the 4th quarter worth $115,000. Finally, Quantbot Technologies LP acquired a new position in Evolus during the 4th quarter worth $118,000. Institutional investors and hedge funds own 90.69% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on EOLS. Barclays upped their price target on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. HC Wainwright reiterated a "buy" rating and set a $27.00 price target on shares of Evolus in a report on Wednesday, March 5th. Finally, Needham & Company LLC restated a "buy" rating and issued a $22.00 price objective on shares of Evolus in a report on Wednesday, March 5th.
Check Out Our Latest Stock Analysis on Evolus
About Evolus
(
Get Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
